Cargando…

Tamoxifen resistance and adjuvant hormone therapy

Detalles Bibliográficos
Autor principal:	Howell, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231903/ http://dx.doi.org/10.1186/bcr1223

Ejemplares similares

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Controversies in the hormonal adjuvant therapy of postmenopausal patients
por: Dowsett, M
Publicado: (2009)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

Gene expression profiles and molecular classification to predict distant metastasis and tamoxifen-resistant breast cancer
por: Klijn, JGM, et al.
Publicado: (2005)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Adjuvant therapy in colorectal cancer – studies of the FOGT group
por: Staib, Ludger, et al.
Publicado: (2010)

Adjuvant therapy after preoperative treatment for breast cancer
por: Ciruelos, E
Publicado: (2009)

Preoperative hormonal therapy: results and implications
por: Dowsett, M
Publicado: (2005)

Growth regulation and steroid hormone resistance in breast cancer
por: Horwitz, KB
Publicado: (2000)

Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer
por: Dowsett, M
Publicado: (2005)

Monophosphoryl Lipid a as an adjuvant for immune therapy? A detailed in vitro comparison to LPS
por: Schülke, Stefan, et al.
Publicado: (2014)

Combined hormonal therapy for advanced breast cancer in postmenopausal patients
por: Langecker, P, et al.
Publicado: (2003)

Hormone replacement therapy, percent mammographic density and the sensitivity of mammography
por: Kavanagh, AM, et al.
Publicado: (2004)

How safe is growth hormone therapy? SAGhE and beyond
por: Carel, Jean-Claude
Publicado: (2013)

Menopause and hormone replacement therapy: effects on the immune system, arthritis and bone
por: Carlsten, H, et al.
Publicado: (2004)

Rationale for adjuvant measures in musculoskeletal diseases
por: Gast, Ulf
Publicado: (2013)

Radically resected node-negative squamous cell carcinoma of thoracic esophagus: recurrence pattern and indication for adjuvant therapy
por: Fang, W, et al.
Publicado: (2013)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

Response to growth hormone therapy and gonadal pathology in 45,X/46,XY females
por: Titmuss, Angela, et al.
Publicado: (2015)

Adjuvant chemotherapy for operable breast cancer: old vs new schema
por: Valagussa, P, et al.
Publicado: (2005)

Predicting response/resistance to endocrine therapy for breast cancer
por: Miller, WR, et al.
Publicado: (2005)

TP53 and additional pathways in therapy resistance
por: Lønning, PE
Publicado: (2005)

Placental hormones and the control of fetal growth
por: Freemark, Michael
Publicado: (2015)

International perspectives on adherence and resistance to HIV antiretroviral therapy
por: Bangsberg, D
Publicado: (2010)

Molecular mechanisms of resistance to HER2-targeted therapy
por: Esteva, FJ
Publicado: (2009)

Hormones and radiation as risk factors for breast cancer
por: Beral, V
Publicado: (2006)

Hormonal interactions during mammary gland development
por: Vonderhaar, BK
Publicado: (2003)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

Increased immunogenicity of HIV vaccination with constant-current electroporation and molecular adjuvants in mice and rhesus macaques
por: Hirao, Lauren, et al.
Publicado: (2006)

How safe is growth hormone treatment during childhood?
por: Cutfield, Wayne
Publicado: (2013)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant
por: Liang, F, et al.
Publicado: (2012)

Surviving starvation: essential role of the ghrelin-growth hormone axis
por: Goldstein, Joseph L, et al.
Publicado: (2012)

Growth hormone responsiveness: why does it vary and can it be predicted?
por: Cutfield, Wayne S
Publicado: (2015)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Identification of genetic markers of resistance to Artemisinin Combination Therapy in the rodent model Plasmodium chabaudi
por: Rodrigues, Louise A, et al.
Publicado: (2010)

Classical versus new prognostic factors for adjuvant treatment selection based on line software to estimate risk and benefit
por: Ravdin, PM
Publicado: (2005)

Dietary triglycerides profoundly affect oral sensitization to peanut protein in an adjuvant-free mouse model of peanut allergy
por: Eckhardt, Erik, et al.
Publicado: (2011)

Non-genomic thyroid hormone signaling through NO/cGMP/PKGII
por: Kalyanaraman, Hema, et al.
Publicado: (2013)

Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?
por: Boyd, Kathleen A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_khui1g22qvfh9aosgm0i66c89m